Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Operating Expenses (2016 - 2025)

Cytosorbents (CTSO) has disclosed Operating Expenses for 14 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 5.54% year-over-year to $9.5 million, compared with a TTM value of $40.3 million through Sep 2025, down 13.09%, and an annual FY2024 reading of $41.9 million, down 21.81% over the prior year.
  • Operating Expenses was $9.5 million for Q3 2025 at Cytosorbents, down from $10.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $17.2 million in Q4 2021 and bottomed at $9.5 million in Q3 2025.
  • Average Operating Expenses over 5 years is $12.2 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 44.66% in 2021, then plummeted 30.23% in 2024.
  • Year by year, Operating Expenses stood at $17.2 million in 2021, then dropped by 29.66% to $12.1 million in 2022, then increased by 20.96% to $14.7 million in 2023, then tumbled by 30.23% to $10.2 million in 2024, then decreased by 6.81% to $9.5 million in 2025.
  • Business Quant data shows Operating Expenses for CTSO at $9.5 million in Q3 2025, $10.4 million in Q2 2025, and $10.1 million in Q1 2025.